Care delivery, health software, and medical technology — private healthcare ranked by latest disclosed valuation.
| # | Company | Valuation | Secondary $/sh | vs Last Round | Last Round | IPO Status |
|---|---|---|---|---|---|---|
| 1 | Neuralink Fremont, California |
$15Bmark 2025-Q2 | no secondary mark | — | Series E · 2025-06-01 · $650M | none |
| 2 | Devoted Health Waltham, MA |
$13Bmark 2023-Q4 | $35.51as of 2026-06-27 | -36.9% | Series F-Prime · 2026-01-30 · $317M | rumored |
| 3 | OpenEvidence Miami, FL |
$12Bmark 2026-Q1 | $454.21as of 2026-06-27 | -6.8% | Series D · 2026-01-21 · $250M | private |
| 4 | Oura Oulu, Finland |
$11Bmark 2025-Q4 | no secondary mark | — | Series E · 2025-10-14 · $900M | rumored |
| 5 | Ro New York, NY |
$7.0Bmark 2025 | no secondary mark | — | Series D · 2022-02-22 · $150M | rumored |
| 6 | Commure Mountain View, CA |
$7.0Bmark 2026-05 | $27.57as of 2026-06-27 | no round comparison | undisclosed | private |
| 7 | Zipline South San Francisco, California |
$6.9Bmark 2026-Q1 | $70.76as of 2026-06-27 | no round comparison | Series H · 2026-03-22 · $800M | Private |
| 8 | WeDoctor Hangzhou, China |
$6.9Bmark 2020-Q4 | no secondary mark | — | Series F · 2020-12-17 · $411M | private |
| 9 | WHOOP Boston, Massachusetts |
$6.7Bmark 2026-Q1 | $7.15as of 2026-06-27 | -36.3% | Series G-2 · 2026-03-30 · $47M | Private |
| 10 | Ro Health New York, NY |
$6.6Bmark 2022-Q1 | $5.46as of 2026-06-27 | -64.4% | Later Stage VC · 2022-01-12 · $150M | private |
| 11 | Doctolib Levallois-Perret, France |
$6.5Bmark 2022-Q1 | no secondary mark | — | Series F · 2022-03-14 · $557M | private |
| 12 | Cityblock New York, NY |
$6.3Bmark 2021-Q3 | $8.64as of 2026-06-27 | -89.0% | Series D · 2021-09-02 · $400M | private |
| 13 | Benchling San Francisco, USA |
$6.1Bmark 2021-Q4 | no secondary mark | — | Series F · 2021-11-18 · $100M | rumored |
| 14 | Alan Paris, France |
$5.9Bmark 2026-Q1 | $14.60as of 2026-06-27 | no round comparison | Later Stage VC · 2026-03-11 · $118M | private |
| 15 | Abridge Pittsburgh, Pennsylvania |
$5.7Bmark 2025-Q2 | $182.57as of 2026-06-27 | +15.2% | Series E · 2025-06-23 · $300M | Private |
| 16 | Lyra Health Burlingame, CA |
$5.6Bmark 2022-Q1 | no secondary mark | — | Funding round · 2024 · $200M | private |
| 17 | Verily Dallas, TX |
$5.0Bmark 2026-Q1 | no secondary mark | — | Strategic recapitalization · 2026-03-19 · $300M | no imminent plans |
| 18 | Cerebral Claymont, DE |
$4.8Bmark 2021-Q4 | $2.55as of 2026-06-27 | no round comparison | Series C · 2021-12-07 · $300M | private |
| 19 | Reify Health Boston, MA |
$4.8Bmark 2022-Q1 | no secondary mark | — | Series D · 2022-01-07 · $217M | private |
| 20 | BetterUp San Francisco, USA |
$4.7Bmark 2021-Q4 | $1.64as of 2026-06-27 | -71.6% | Series E · 2021-10-12 · $300M | private |
| 21 | Color Burlingame, CA |
$4.6Bmark 2021-Q4 | $12.24as of 2026-06-27 | -87.8% | Series E · 2021-11-08 · $100M | private |
| 22 | Sword Health New York, NY |
$4.5Bmark 2025-Q2 | $27.83as of 2026-06-27 | -61.1% | Series F · 2025-06-17 · $40M | private |
| 23 | Medlinker Chengdu, China |
$4.0Bmark 2020-Q4 | no secondary mark | — | Series E · 2020-12-31 · $514M | private |
| 24 | PointClickCare Toronto, Canada |
$4.0Bmark 2018-Q1 | no secondary mark | — | Private Equity · 2018-02-28 · $146M | private |
| 25 | Noom New York, NY |
$3.7Bmark 2024-Q2 | $2.98as of 2026-06-27 | no round comparison | Series F · 2021-05-25 · $540M | rumored |
| 26 | Ultima Genomics Fremont, CA |
$3.6Bmark 2022-Q2 | $24.96as of 2026-06-27 | -50.2% | Series E · 2022-05-31 · $229M | private |
| 27 | Hippocratic AI Palo Alto, CA |
$3.5Bmark 2025-11 | $26.33as of 2026-06-27 | 0.0% | Series C · 2025-11-01 · $141M | no imminent plans |
| 28 | Everly Health Austin, TX |
$3.5Bmark 2021-Q1 | $16.14as of 2026-06-27 | -75.0% | Series F · 2021-03-23 · $154M | private |
| 29 | Spring Health New York, NY |
$3.3Bmark 2024-Q3 | $31.24as of 2026-06-27 | -54.0% | Series E · 2024-07 · $100M | private |
| 30 | Komodo Health New York, NY |
$3.3Bmark 2021-Q1 | $13.86as of 2026-06-27 | -72.8% | Series E · 2021-03-21 · $220M | private |
| 31 | Judi Health New York, NY |
$3.3Bmark 2025-Q3 | $15.12as of 2026-06-27 | +12.1% | Series F · 2025-09-08 · $400M | private |
| 32 | Cedar New York, NY |
$3.2Bmark 2021-Q2 | $23.55as of 2026-06-27 | no round comparison | Later Stage VC · 2021-06-16 · $268M | private |
| 33 | Headspace Santa Monica, CA |
$3.0Bmark 2021-Q3 | $4.43as of 2026-06-27 | +47.7% | Merger (Headspace + Ginger) · 2021-08-01 | no imminent plans |
| 34 | Grow Therapy New York, NY |
$3.0Bmark 2026-Q1 | $10.15as of 2026-06-27 | no round comparison | Series D · 2026-03-03 · $150M | private |
| 35 | CMR Surgical Cambridge, United Kingdom |
$3.0Bmark 2025-Q2 | no secondary mark | — | Later Stage VC · 2025-04-02 · $200M | private |
| 36 | OYO Rooms Gurugram, India |
$2.9Bmark 2024-Q3 | $0.25as of 2026-06-27 | -28.6% | Series G · 2024-07-04 · $349M | private |
| 37 | Transcarent Denver, CO |
$2.7Bmark 2025-Q2 | $10.38as of 2026-06-27 | -49.3% | Series D1 · 2025-04-06 · $200M | private |
| 38 | Somatus McLean, VA |
$2.6Bmark 2022-Q1 | $800.00as of 2026-06-27 | -8.3% | Series E · 2022-02-23 · $325M | private |
| 39 | Function Health Austin, TX |
$2.5Bmark 2025-Q4 | $60.00as of 2026-06-27 | no round comparison | Series B · 2025-11-19 · $298M | private |
| 40 | DispatchHealth Denver, CO |
$2.4Bmark 2021-Q1 | $904.75as of 2026-06-27 | -22.7% | Series E · 2021-03-03 · $200M | private |
| 41 | Headway New York, NY |
$2.3Bmark 2024-Q3 | $6.95as of 2026-06-27 | -42.1% | Series D · 2024-07 · $100M | private |
| 42 | Strava San Francisco, California |
$2.2Bmark 2025-Q2 | $9.04as of 2026-06-27 | -35.4% | Series F-1 · 2025-05-21 · $50M | Confidentially filed for IPO |
| 43 | Freenome Brisbane, CA |
$2.2Bmark 2024-Q1 | $1.48as of 2026-06-27 | -80.0% | Later Stage VC · 2024-02-14 · $254M | private |
| 44 | Hotel Engine Denver, CO |
$2.1Bmark 2024-Q3 | $14.34as of 2026-06-27 | -18.6% | Series C · 2024-09-17 · $140M | private |
| 45 | Medable Palo Alto, CA |
$2.1Bmark 2021-Q4 | $3.00as of 2026-06-27 | -69.0% | Series D · 2021-10-24 · $304M | private |
| 46 | Unite Us New York, NY |
$2.1Bmark 2021-Q4 | $58.74as of 2026-06-27 | -76.4% | Series C · 2021-11-17 · $185M | private |
| 47 | Calm San Francisco, USA |
$2.0Bmark 2022-Q1 | $2.17as of 2026-06-27 | -86.3% | Series C · 2022-02-15 · $75M | private |
| 48 | Virta Health Denver, CO |
$2.0Bmark 2024 | no secondary mark | — | Series E · 2021 · $133M | rumored |
| 49 | Noah Medical San Carlos, CA |
$2.0Bmark 2025-Q3 | $5.00as of 2026-06-27 | -57.8% | Series B1 · 2025-09-23 · $230M | private |
| 50 | ZnanyLekarz (Docplanner) Warsaw, Poland |
$1.8Bmark 2021-Q3 | no secondary mark | — | Series F · 2021-09-01 | private |
Methodology. Rankings are by each company's latest disclosed valuation (roster + weekly enrichment); the "mark" chip shows when that valuation was set. Secondary share prices are point estimates from secondary-market activity — one implied price per name, no bid/ask — refreshed daily (marks overlay as of 2026-08-16), each carrying its own date. "vs Last Round" compares the secondary price to the company's own last primary round per-share price; rows without a usable comparison say so rather than showing zero. Companies marked acquired, defunct, or public are excluded. Educational data, not investment advice.